Project Grant F32CA306127
- The National Cancer Institute (NCI), through its Cancer Biology Research program (CFDA 93.396), has awarded a $1,281,520 Cooperative Agreement to The Leland Stanford Junior University (Stanford University) to conduct a multi-year research project titled "Multiplexed Dissection of Metastatic Ability, Organ Tropism, and Immune Evasion." The research aims to uncover the fundamental drivers of metastasis and immune evasion in pancreatic ductal adenocarcinoma (PDAC) using innovative...
- This $299,168.00 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to New York University (NYU) School of Medicine will fund research to optimize surgical decision-making for premalignant pancreatic cysts, specifically intraductal papillary mucinous neoplasms (IPMNs). The key objectives are to: 1) Quantify individualized risk of cancer in IPMNs, 2) Elicit patient preferences to inform decisions about surgery versus surveillance, and 3) Develop a...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $739,640 to the Fred Hutchinson Cancer Center in Seattle, Washington to develop methods for advancing the early detection of pancreatic ductal adenocarcinoma (PDAC) by leveraging electronic medical records (EMR) data. The research aims to better define at-risk populations for PDAC, such as individuals with new-onset prediabetes or worsening long-standing...
- The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Johns Hopkins University for $653,819 on Feb 24, 2025. The grant's objectives are to: Develop a highly specific blood-based early detection screening test, PancSeek, for populations at higher risk of pancreatic cancer. Develop risk models that integrate clinical, genomic, molecular, and imaging data to enable personalized surveillance management plans for...
- The National Cancer Institute (NCI) awarded a $191,700 Project Grant to Cedars-Sinai Medical Center under the Cancer Research Manpower (CFDA 93.398) federal grant program. The grant supports research to identify modifiable factors associated with the development of early-onset pancreatic cancer and characterize the clinicopathologic and molecular features of tumors in affected patients. Specifically, the project aims to investigate the associations of early-onset pancreatic cancer with...
- The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) in the amount of $677,176 to The Research Foundation For The State University Of New York (RF SUNY) on April 11, 2025. The goal of this project is to translate the concept of Interstitial Chemophototherapy (I-CPT) as a tumor ablation paradigm for locally advanced pancreatic cancer (PACA). The funding will advance the development of long-circulating liposomal irinotecan with...
- The National Cancer Institute (NCI) awarded a $858,166 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The General Hospital Corporation (Massachusetts General Hospital) to conduct a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The study aims to improve documentation of end-of-life care preferences, delivery of end-of-life care, and patient-reported outcomes for this vulnerable population. The project...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $109,080 to The Trustees of Columbia University in the City of New York to conduct a Phase II, randomized controlled trial evaluating the clinical efficacy of a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma. The trial compares a combination therapy regimen of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel against the standard of care...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Sloan-Kettering Institute for Cancer Research provides $263,086 to develop a multiparametric endoscopic ultrasound (MPEUS) imaging system and methodology for improved pancreatic cancer screening and characterization. The goal is to create a non-subjective, quantitative approach for detecting and characterizing pancreatic cancer and precursor lesions in high-risk...
- This $110,550 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research at the University of Pennsylvania to investigate the mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma. The primary objectives are to 1) evaluate transient, single lymph node regulatory T cell depletion as a therapeutic strategy to treat lymph node metastasis, and 2) examine how lymph nodes promote anti-tumor immune...
ENHANCING ACCESS IN PANCREATIC CANCER: EXAMINING FACILITATORS AND BARRIERS TO TERTIARY REFERRAL FOR COMPLEX ONCOLOGIC SURGICAL CARE. - PANCREATIC CANCER CONTINUES TO REPRESENT A SIGNIFICANT BURDEN OF CANCER-RELATED MORTALITY BOTH IN THE UNITED STATES AND GLOBALLY, WITH 5-YEAR SURVIVAL ONLY 12.8% DESPITE RECENT TREATMENT ADVANCES. FOR PATIENTS WITH EARLY-STAGE DISEASE, MULTI-MODAL TREATMENT INCLUDING SURGERY IS THE ONLY POTENTIALLY CURATIVE THERAPY. NEVERTHELESS, SURGICAL INTERVENTION REMAINS UNDERUTILIZED NATIONALLY - FEWER THAN 50% OF ELIGIBLE PATIENTS WITH NON-METASTATIC DISEASE PROCEED WITH RESECTION. FURTHERMORE, SIGNIFICANT BARRIERS PERSIST IN THE DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER, WHICH LIMITS ACCESS TO ADVANCED SURGICAL CARE AND SPECIALIZED ONCOLOGIC THERAPIES. NOTABLY, PRIOR STUDIES HAVE LARGELY FOCUSED ON PATIENT CHARACTERISTICS SUCH AS AGE, EDUCATION LEVEL, AND SOCIOECONOMIC STATUS, MANY OF WHICH ARE NON-MODIFIABLE. PROVIDER- AND SYSTEM-LEVEL FACTORS THAT AFFECT SURGICAL REFERRAL PATTERNS HAVE NOT BEEN THOROUGHLY STUDIED BUT ARE LIKELY MORE AMENABLE TO POLICY AND QUALITY IMPROVEMENT INTERVENTIONS. THE CENTRAL OBJECTIVE OF THIS MIXED METHODS RESEARCH STUDY IS TO EXAMINE THE ETIOLOGY OF THE UNDERUTILIZATION OF SURGICAL RESECTION IN EARLY-STAGE PANCREATIC CANCER BY ANALYZING THE FACILITATORS AND BARRIERS TO TERTIARY REFERRAL, FOCUSING ON PROVIDER AND SYSTEM FACTORS THAT IMPACT REFERRAL TO COMPLEX CANCER SURGEONS AT MULTIDISCIPLINARY CENTERS. FIRST, A QUANTITATIVE ANALYSIS OF A NATIONAL CANCER DATABASE WILL BE PERFORMED TO CREATE AN EXPLANATORY MODEL FOR REFERRAL PATTERNS, HIGHLIGHTING RELEVANT PROVIDER-, PRACTICE-, AND SYSTEM-LEVEL FACTORS. A SUB-ANALYSIS WILL BE PERFORMED, STRATIFYING BY PATIENT DEMOGRAPHIC FACTORS IN THE MULTIVARIABLE MODELS, TO IDENTIFY FACTORS THAT MAY BE DIFFERENTIALLY ASSOCIATED WITH REFERRAL OR RECEIPT OF SURGERY BETWEEN PATIENT GROUPS. NEXT, QUALITATIVE ANALYSIS EMPLOYING SEMI-STRUCTURED INTERVIEWS OF VARIOUS STAKEHOLDERS ACROSS THE PANCREATIC CANCER CARE CONTINUUM WILL BE COMPLETED TO IDENTIFY FACILITATORS AND BARRIERS TO REFERRAL. INTERVIEWS WILL INCLUDE BOTH PHYSICIAN AND NON-PHYSICIAN PROVIDERS FROM BOTH ACADEMIC AND COMMUNITY CENTERS ACROSS MASSACHUSETTS IN ORDER TO CAPTURE COMPREHENSIVE PERSPECTIVES REGARDING RELEVANT FACTORS UPSTREAM OF THE SURGICAL ENCOUNTER. THE PROJECT'S FOCUS ON PROVIDER- AND SYSTEM-LEVEL FACTORS, RATHER THAN PATIENT CHARACTERISTICS, WILL BETTER ENABLE IDENTIFICATION OF POTENTIAL CAUSAL PATHWAYS AND ILLUMINATE MODIFIABLE TARGETS FOR HEALTH SYSTEM AND QUALITY IMPROVEMENT INTERVENTIONS. THE KNOWLEDGE GAINED FROM THIS WORK WILL THEREFORE HELP ENHANCE SURGICAL ACCESS, OPTIMIZE CANCER CARE, AND IMPROVE PATIENT OUTCOMES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $11.5k | 9/16/25 | ||
| Not listed | $0 | 8/21/25 | ||
| Not listed | $82.5k | 8/21/25 |